102 related articles for article (PubMed ID: 24657802)
1. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
[TBL] [Abstract][Full Text] [Related]
2. A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
Cao C; Fu Z; Liu Y; Zhou A; Wang J; Shou J
Front Immunol; 2021; 12():684879. PubMed ID: 34177933
[TBL] [Abstract][Full Text] [Related]
3. Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.
Keegan KA; Zaid HB; Patel SG; Chang SS
Curr Urol Rep; 2014 Apr; 15(4):394. PubMed ID: 24566815
[TBL] [Abstract][Full Text] [Related]
4. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.
Chang PH; Chen HY; Chang YS; Su PJ; Huang WK; Lin CF; Hsieh JC; Wu CT
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473256
[TBL] [Abstract][Full Text] [Related]
5. Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.
Weiss K; Abimbola O; Miller K; Kim WY; Rose TL; Bjurlin MA; Gessner KH
Urology; 2024 Feb; 184():75-78. PubMed ID: 38052324
[TBL] [Abstract][Full Text] [Related]
6. Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
Saunders KE; Gerken N; Khani F; Williamson SR; Wobker SE
Am J Clin Pathol; 2024 May; 161(5):483-489. PubMed ID: 38240078
[TBL] [Abstract][Full Text] [Related]
7. Current Concepts in the Management of Muscle Invasive Bladder Cancer.
Krishna SR; Konety BR
Indian J Surg Oncol; 2017 Mar; 8(1):74-81. PubMed ID: 28127187
[TBL] [Abstract][Full Text] [Related]
8. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer.
Jayaratna IS; Navai N; Dinney CP
Transl Androl Urol; 2015 Jun; 4(3):273-82. PubMed ID: 26816830
[TBL] [Abstract][Full Text] [Related]
9. Precision oncology in urothelial cancer.
Liow E; Tran B
ESMO Open; 2020 Mar; 5(Suppl 1):e000616. PubMed ID: 32132102
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of muscle-invasive bladder cancer - a review.
Scarpato KR; Morgans AK; Moses KA
Res Rep Urol; 2015; 7():143-51. PubMed ID: 26380230
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years.
Raghavan D
Bladder Cancer; 2015 Apr; 1(1):3-13. PubMed ID: 30561439
[TBL] [Abstract][Full Text] [Related]
12. Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
Suartz CV; Martinez LM; Cordeiro MD; Botelho LAA; Gallutti FP; Mota JM; Leite KRM; Toren P; Nahas WC; Ribeiro-Filho LA
Clin Genitourin Cancer; 2024 Apr; 22(3):102087. PubMed ID: 38688207
[TBL] [Abstract][Full Text] [Related]
13. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder.
Bhatt VR; Loberiza FR; Tandra P; Krishnamurthy J; Shrestha R; Wang J
Rare Tumors; 2014 Jan; 6(1):5043. PubMed ID: 24711904
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for advanced bladder cancer.
Sonpavde G; Elfiky AA; Rosenberg JE
Ther Adv Med Oncol; 2009 Jul; 1(1):37-50. PubMed ID: 21789112
[TBL] [Abstract][Full Text] [Related]
15. Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
Kim S; St-Laurent MP; Black P
Transl Androl Urol; 2024 Mar; 13(3):458-462. PubMed ID: 38590957
[No Abstract] [Full Text] [Related]
16. Super-responders to bidirectional neoadjuvant chemotherapy showed prolonged survival.
Sugarbaker PH; Van der Speeten K
J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S57-S58. PubMed ID: 33970162
[No Abstract] [Full Text] [Related]
17. Editorial: Expert opinions in genitourinary oncology.
Lagos GG; El-Deiry WS; Cheng L
Front Oncol; 2023; 13():1360223. PubMed ID: 38344145
[No Abstract] [Full Text] [Related]
18. Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients.
Klemm J; Laukhtina E; Shariat SF
Nat Rev Clin Oncol; 2024 Feb; 21(2):87-88. PubMed ID: 37978331
[No Abstract] [Full Text] [Related]
19. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD; Daneshmand S; Izadmehr S; Gonzalez-Kozlova E; Chan KG; Lewis S; Achkar BE; Dorff TB; Cetnar JP; Neil BO; D'Souza A; Mamtani R; Kyriakopoulos C; Jun T; Gogerly-Moragoda M; Brody R; Xie H; Nie K; Kelly G; Horowitz A; Kinoshita Y; Ellis E; Nose Y; Ioannou G; Cabal R; Del Valle DM; Haines GK; Wang L; Mouw KW; Samstein RM; Mehrazin R; Bhardwaj N; Yu M; Zhao Q; Kim-Schulze S; Sebra R; Zhu J; Gnjatic S; Sfakianos J; Pal SK
Nat Med; 2023 Nov; 29(11):2825-2834. PubMed ID: 37783966
[TBL] [Abstract][Full Text] [Related]
20. Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature.
Wu J; Xie RY; Cao CZ; Shang BQ; Shi HZ; Shou JZ
Front Oncol; 2022; 12():816444. PubMed ID: 35494010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
